CRNX Crinetics Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRNX

Price (delayed)

$34.68

Market cap

$3.66B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.13

Enterprise value

$3.59B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 23

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, ...

Highlights
CRNX's gross profit has soared by 154% from the previous quarter
The revenue has soared by 135% since the previous quarter
The quick ratio has soared by 51% QoQ but it has decreased by 18% YoY
The gross margin has increased by 8% QoQ but it has decreased by 7% YoY
CRNX's net income has dropped by 51% year-on-year and by 7% since the previous quarter
The company's EPS fell by 35% YoY and by 3.6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.crinetics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRNX

CRNX stock price

How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
4.81%
1 week
-3.69%
1 month
-15.93%
1 year
7.94%
YTD
-25.5%
QTD
-4.52%

Financial performance

How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$18.07M
Gross profit
$16.79M
Operating income
-$545.74M
Net income
-$496.39M
Gross margin
92.9%
Net margin
-2,747.2%
CRNX's gross profit has soared by 154% from the previous quarter
The revenue has soared by 135% since the previous quarter
The net margin has surged by 94% year-on-year and by 55% since the previous quarter
The operating margin has soared by 94% YoY and by 55% from the previous quarter

Price vs fundamentals

How does CRNX's price correlate with its fundamentals

Growth

What is Crinetics Pharmaceuticals's growth rate over time

Valuation

What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.84
P/S
199.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
198.69
The company's EPS fell by 35% YoY and by 3.6% QoQ
CRNX's equity is up by 29% since the previous quarter and by 2.1% year-on-year
CRNX's P/B is 23% below its 5-year quarterly average of 3.5 and 18% below its last 4 quarters average of 3.3
The revenue has soared by 135% since the previous quarter
The P/S is 86% below the 5-year quarterly average of 1373.4 and 86% below the last 4 quarters average of 1318.1

Efficiency

How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales has surged by 94% YoY and by 55% QoQ
The company's return on equity fell by 42% YoY and by 6% QoQ
The ROA has decreased by 41% YoY and by 6% from the previous quarter
The return on invested capital has declined by 22% year-on-year and by 7% since the previous quarter

Dividends

What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRNX.

Financial health

How did Crinetics Pharmaceuticals financials performed over time
The current ratio has soared by 51% from the previous quarter but it has contracted by 17% YoY
The quick ratio has soared by 51% QoQ but it has decreased by 18% YoY
The debt is 96% smaller than the equity
CRNX's equity is up by 29% since the previous quarter and by 2.1% year-on-year
CRNX's debt to equity is down by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.